Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Immunosuppression in liver transplantation: beyond calcineurin inhibitors Fung J; Kelly D; Kadry Z; Patel-Tom K; Eghtesad BLiver Transpl 2005[Mar]; 11 (3): 267-80Although calcineurin inhibitors (CNIs) remain the mainstay of immunosuppression in liver transplantation (LTX), their long-term toxicity significantly contributes to morbidity and mortality. The elucidation of mechanisms of alloimmunity and leukocyte migration have provided novel targets for immunosuppression development. The toxicities of these agents differ from that of the CNI and act additively or synergistically. CNI avoidance protocols in LTX have not been achieved routinely; however, pilot trials have begun to delineate the limitations and promises of such approaches. CNI-sparing protocols appear to be much more promising in balancing the early need for minimizing rejection while tapering doses and minimizing long-term toxicity.|*Calcineurin Inhibitors[MESH]|Adrenal Cortex Hormones/therapeutic use[MESH]|Alemtuzumab[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antibodies, Neoplasm/therapeutic use[MESH]|Antibody Formation[MESH]|Antilymphocyte Serum/therapeutic use[MESH]|Humans[MESH]|Immunosuppression Therapy/*trends[MESH]|Immunosuppressive Agents/*therapeutic use[MESH]|Liver Transplantation/*immunology[MESH]|Mycophenolic Acid/therapeutic use[MESH]|Sirolimus/therapeutic use[MESH]|T-Lymphocytes/immunology[MESH] |
